Interestingly, although both the ERK1/2 signaling pathway and the NFκB signaling pathway are reported to associated with cancer development, during malignant transformation and metastasis [53,54], only the ERK1/2 signaling pathway is enriched in the early (R/M≤6months) recurrence/metastasis patients. Here, NFKB1 is linked to cancer.